Objective: Intraoperative detection of ovarian sentinel nodes has been shown to be feasible. We examined the detection rate and locations of sentinel nodes in patients with ovarian tumors. We also aimed to assess the reliability of sentinel node method in predicting regional lymph node metastasis. Methods: Twenty patients scheduled for laparotomy because of a pelvic mass were recruited to the study. In the beginning of the laparotomy, radioisotope and blue dye were injected under the serosa next to the junction of the ovarian tumor and suspensory ligament. The number and locations of the hot and/or blue nodes/spots were recorded during the operation. If the tumor was malignant according to the frozen section, systematic lymphadenectomies were performed, the sentinel nodes sampled separately, and their status compared with other regional lymph nodes. Results: Eleven patients had a right-sided ovarian tumor, 7 patients a left-sided tumor, and 2 patients had bilateral tumors. A median of 2 sentinel nodes/locations per patient (range, 1Y3) were found. Sixty percent of all sentinel nodes were located in the para-aortic region only, compared with 30% in both para-aortic and pelvic areas and 10% in pelvic area only. Both unilateral and bilateral locations were found. In 83% of the cases with more than 1 sentinel node location, they were located in separate anatomical regions. In 3 patients, systematic lymphadenectomies were performed. One of them had nodal metastases in 2 regions and also a metastasis in 1 of her 2 sentinel nodes in 1 of those regions. Conclusions: In patients with ovarian tumor(s), the detection of sentinel nodes is feasible. They are located in different anatomic areas both ipsilaterally and contralaterally, although most of them are found in the para-aortic region. The reliability of the sentinel node concept should be evaluated in the framework of a multicenter trial.
(IMA) and the renal vein, superficial iliac nodes, and nodes from the obturator fossa. 1 Moreover, larger number of removed nodes increases the likelihood of finding more lymph node metastasis. 2 On the other hand, the increasing extent of lymphadenectomy carries increasing risk of serious complications, 1 the blood loss and proportion of patients transfused, the duration of the surgery and the length of hospital stay. 3 During the surge of mini-invasive surgery in gynecological cancer, sentinel node (SN) concept has been adopted into surgery of early vulvar, cervical, and endometrial cancer. 4 In early ovarian cancer, the concept has been mainly overlooked because of a laborious reachability of the intra-abdominal injection site, a presumption of the slowness of commonly used tracers, and a fear of spillage of tumor cells following the injection.
In 2011, Nyberg et al 5 reported a successful intraoperative use of blue dye and technetium isotope in detection of ovarian SNs after tracer injection into a normal postmenopausal ovary in patients with high-risk uterine cancer. The SN detection rate during systematic lymphadenectomies in a series of 16 patients was 94%, and all SNs were located in the PA regions. Three years later, Kleppe et al 6 described that the use of blue dye and radioisotope in ovarian tumor patients was successful in finding SN locations in all of their 21 patients. They injected the tracers into 2 sites in ovarian ligaments outside the suspicious tumor to prevent any potential dissemination of cancer cells. After injection, they located the hot SN sites transperitoneally with a gamma detector and retroperitoneally, if the tumors proved to be malignant and lymphadenectomies were carried out. 6 With our patient series, we wanted to examine the detection rate and locations of SNs by conventional tracers (blue dye and radioisotope) in patients with suspicious ovarian masses. We also aimed to evaluate the reliability of SN method in predicting regional lymph node metastasis, in case the mass proved to be malignant in frozen-section analysis.
MATERIALS AND METHODS
From December 2010 through September 2013, 20 eligible women with either unilateral or bilateral ovarian masses were recruited to the study. The inclusion criteria were as follows: scheduled open surgery (total abdominal hysterectomy and bilateral salpingo-oophorectomy) to remove the suspicious mass(es), which was estimated to involve the ovary/adnexa only. In premenopausal women with intact uterus, also a negative pregnancy test within 24 hours before surgery was required. The exclusion criteria were as follows: previous allergic reaction to blue dye or human albumin and signs of malignant spread to the abdominal cavity in preoperative imaging. Ascites alone and/or elevated serum CA-125 without any other sign of dissemination were not exclusive.
The patient demographics, previous operative history, and the largest diameter of the ovarian tumor(s) from each patient were recorded.
In the beginning of each laparotomy, the adnexal mass (or masses) was exposed. This sometimes required liberation of adhesions and/or lifting the large tumor outside the abdominal cavity. Then, 1 mL of technetium Tc 99mYlabeled human albumin colloid (Nanocoll; GE Heathcare, Saluggia, Italy) was slowly injected to 1 spot under the serosa next to the lateral junction of the ovarian tumor (mesovarium) with a 27-gauge needle (Fig. 1) . The preparation of the radiopharmaceutical was performed in the Department of Nuclear Medicine on the same day. The needle was then kept in its place, the syringe changed, and 2 mL of patent blue dye (Bleu Patenté V; Guerbet, Paris, France) was injected to the same spot, to prevent the tracers to spill out from multiple needle holes and stain the operation field. In the case of bilateral tumors, the tracers were injected to both sides.
After a minimum of a 10-minute interval, during which the abdominal cavity was examined, the peritoneal cytology taken, and the passage of the blue dye noted, the adnexal mass or masses were removed, opened, and sent to a pathologist for frozen-section analysis. After that, the operation was continued with hysterectomy (unless previously removed). If the mass was benign or borderline not needing lymphadenectomies, the pelvic and PA areas were then closely examined transperitoneally for the visible blue dye and extra radiation without opening the peritoneum or removing the nodes. A count rate of at least 10 times the background radiation was thought to represent a ''hot'' spot and SN location, using a handheld gamma detector (Neo2000; Neoprobe, Dublin, OH). The number and locations of each blue and/or hot spots were marked on a map, which contained all significant lymphatic regions including upper PA and PC areas (above IMA), lower PA/PC area (below IMA), right and left common iliac area (upper pelvic area), right and left external iliac area, and right and left obturator area (lower pelvic area), as well as the method of their detection. In the case of a borderline tumor, a complete surgical staging (peritoneal biopsies, omentectomy, appendicectomy) was then performed. If the tumor was malignant, systematic FIGURE 1. The injection spot of the tracers to the mesovarium.
pelvic and PA lymphadenectomies were carried out as a part of complete surgical staging, when technically possible. After opening the peritoneum, all retroperitoneally detected SNs (hot and/or blue) were sampled separately, and their location marked on the map similarly as above.
The non-SNs were processed according to a standard protocol for lymph node examination; they were cut into single sections or, if more than 1 cm in diameter, into 2 to 3 sections and stained with hematoxylin-eosin before microscopy. The SNs were cut into 2-mm sections for hematoxylineosin staining. Ultrastaging and immunohistochemistry were not used. All detected metastases and their locations were recorded, and the status of each SN was compared with the status of the non-SNs in the same region.
Pearson correlation coefficient was used to estimate the association between tumor size and SN number. P G 0.05 considered statistically significant.
The study protocol was approved by the local ethics committee of Pirkanmaa Hospital District (approval no. R10072). A written informed consent was obtained from all patients.
RESULTS
Twenty women, with median age of 63.3 years (range, 41.1Y80.7 years) and body mass index (BMI) of 25.8 kg/m 2 (range, 21.5Y36.1 kg/m 2 ), were enrolled. The patient data are shown in Table 1 . In women with previous open surgeries, a careful liberation of adhesions had to be made before the injection site was properly exposed. Two tumors were torquated (patients 12 and 18), and the latter also buried under adhesions requiring liberation. The distribution of the tumor aspects is shown in Table 2 . The median preoperative diameter of the right-sided tumors was 11 cm (range, 5Y20 cm) and that of the left-sided tumors 7 cm (range, 3.5Y21 cm). One right-sided tumor was found to be ruptured, and according to the symptoms of the patient, that had happened the night before surgery. Both tracers were successfully injected as described previously all 20 women, and no adverse or allergic reactions were noted. The median injected activity of Nanocoll to 1 side was 20.0 MBq (range, 17.0Y26.6 MBq). The median interval between the tracer injections and the beginning of the removal of the tumor(s) was 12 minutes (range, 10Y33 minutes). During the operation, 11 women had benign frozen sections, and the final histopathologic examination confirmed those results. Four women had borderline tumors. In 1 case (patient 17), the pathologist could not exclude invasion based on the frozen section. As there were also palpable prominent lymph nodes on the right PA region, systematic lymphadenectomies were carried out, and 3 hot and blue SNs were found and sampled on that area. The final diagnosis was serous borderline tumor, with endosalpingiosis present in 2 of 3 SNs.
Five women had a malignant disease (patients 7, 8, 15, 16, and 20). During the examination of the abdominal cavity, an unexpected carcinosis was found in 2 of them (patients 8 and 16). Patient 8 had a final diagnosis of International Federation of Gynecology and Obstetrics stage 3a2 serous ovarian cancer with suboptimal surgical result, and patient 16 had a breast cancer metastasis in the right ovary, spreading to the abdominal cavity. In both, SN locations (1 and 3, respectively) were transperitoneally detected and mapped. Patient 20 had a BMI of 36.1 kg/m 2 , and because of technical difficulties, the lymphadenectomies were passed, but 1 hot SN location was found and mapped. Altogether, systematic lymphadenectomies with separate SN samplings were performed to 3 patients (15% of study population), and in the rest of the patients, a transperitoneal SN mapping was carried out.
We were able to locate 1 to 3 SNs (median of 2) from each woman, resulting in total of 36 SN sites. For both rightand left-sided tumors, the mean number of SNs was 2, with a range of 1 to 3 and 1 to 2, respectively. In the case of bilateral tumors, the median number of SNs was 2 (range, 2Y3). There was no correlation between the size of the tumor and the number of detected SN sites per patient (r 2 = 0.0012, 2-sided P = 1.00). In 12 patients (60%), more than 1 SN was found, and in 10 cases (83%), they were located in the separate anatomical regions. The distribution of SN locations and laterality according to the tumor side are shown in Table 2 . In 18 patients with unilateral tumors, most of the SN sites were ipsilateral (83%, 15 patients), and contralateral only in 1 patient (6%), whereas bilateral SN sites were found in 11% (2 patients). With bilateral ovarian masses, all the SN sites were detected bilaterally.
The regional distributions of all SNs are shown in Figure 2 . Seventy-eight percent (28/36) of all SN sites were located in the PA region. In 12 (60%) of 20 patients, it was the only region where SNs were detected. In 6 (30%) of patients, both PA and pelvic SN locations were seen together. In only 2 patients (10%), the SNs were found solely in the pelvis.
The left-ovaryYrelated SN sites seemed to be located higher than those related to the right ovary; 64% versus 30% were located above the IMA, respectively. Whereas 18% of the left-ovaryYrelated SN sites were traced to the upper pelvic (common iliac) region, no SN sites were found in the lower pelvic area. Ten percent of the right-ovaryYrelated SN sites were found in the upper pelvic region (common iliac region), and 10% in the lower pelvic region. The tracers seemed to cross the midline from left to right only above the IMA level, whereas crossover from right to left was observed in the upper pelvic, lower PA, and upper PA regions.
The results of the 3 patients with systematic lymphadenectomies are shown in Table 3 . Eighteen of all SNs (50%) were detected both visually and with gamma detector, 17 (47%) by means of radiation only, and 1 (3%) only visually. With transperitoneal mapping (28 SN locations), 43% (12 SNs) were found by combining dye and radiotracer, 54% (15 SNs) with radiation only, and 4% (1 SN) with dye only. Eight SNs were collected in lymphadenectomized patients, 75% (6 SNs) with combined method and 25% (2 SNs) by using gamma detector. The median intervals between injections and identification of SNs were 56 minutes (28Y126 minutes) transperitoneally and 129 minutes (49Y180 minutes) retroperitoneally.
DISCUSSION
With a detection rate of 100%, our results confirm that blue dye and radioisotope are swiftly transported from the mesovarium to the regional lymph nodes and that perioperative SN mapping is feasible in patients with ovarian tumors.
The distribution of SN sites in our study is in line with literature concerning lymph node metastases in apparent early ovarian cancer (EOC). According to a review with more than 1200 EOC cases, PA metastases alone were found in 50% of patients, both PA and pelvic metastases in 30% of patients, and pelvic metastases alone in 20% of patients. In case of a unilateral tumor, 56% of the metastases were ipsilateral, 21% contralateral, and 41% bilateral (2) .
In the present study, the left-ovaryYrelated SNs were located either in the PA (71%) or PA and upper pelvic (29%) areas, whereas the right-ovaryYrelated SNs were located PA (64%), PA and pelvic (18%), or solely pelvic (18%) areas, including also the lower pelvis. The left-ovaryYrelated SNs were more often found above the IMA level than the rightovaryYrelated SNs (64% vs 30%, respectively). With unilateral tumors, unilateral SNs were more common than bilateral SNs (89% vs 11%). Nyberg et al 5 reported 64% of the leftovaryYrelated SNs to be located above the IMA level, whereas 94% of the right-ovaryYrelated SNs were located below the IMA level. In that series, no bilateral or contralateral SNs were found. Kleppe et al 6 reported most of their SN locations being traced to the PA/PC region (67%), as only 9% were traced to the pelvis and 24% to both regions. Ninetythree percent of SN locations were ipsilateral. In their study, half of transperitoneally detected SN sites related to the left ovary were located in the ipsilateral upper PA area, compared with 45% of the SN sites related to the right ovary. All their removed SNs after left-sided injections were found high in the upper left PA area, but the SNs after right-sided injections were mainly located at the IMA level (6) . This asymmetry, present in all 3 studies, may be a reflection of the asymmetrical drainage of the right and left ovarian veins.
It has been purported that the tracers should be injected to both ovarian ligaments. 6, 7 According to a recent article, 3 lymphatic drainage pathways from the ovaries can be distinguished. The 2 main routes drain the ovaries via the suspensory ligament toward the PA/PC areas and via the proper ligament of the ovaries toward the obturator fossa and the internal iliac artery. The third minor pathway drains the ovaries via the round ligament to the inguinal lymph nodes but is probably present only in a small percentage of people. This study did not find any connections between right and left ovarian drainage, nor did it explain the asymmetry of lymphatic networks between right and left ovaries. It, however, described that a considerable number of lymphatic vessels are present in mesovarium along the entire length of the ovary. 7 To our experience, the tracers leak out from the tiniest holes and smudge the operation field, hampering the visibility of blue-stained lymphatics and the use of gamma detector in pelvis. Our 1-spot injection to the mesovarium gave similar SN distribution results compared with the study by Kleppe et al, 6 although they injected the tracers to both ovarian ligaments. Although one should be cautious in making firm conclusions based on small materials, it seems unnecessary to use multiple injection spots. In the present study, blue dye was observed transperitoneally in less than half of the cases. Retroperitoneally explored, 75% of the hot nodes were also blue stained. In the study of Kleppe et al, 6 blue staining was not recorded at all in transperitoneal mapping. In retroperitoneal exploration, they identified blue dye in only one third of the patients. 6 The visibility of blue dye depends on the interval between the injection and mapping and the thickness of the tissue around the lymphatic vessels. To our experience, blue dye shows where to seek for the radiation. However, a lack of blue staining does not exclude the possibility of hot nodes. A new tracer indocyanine green is reported to have an improved tissue penetration compared with blue dye. Replacing blue dye with it might enhance the visibility. The results in endometrial and cervical cancer have certainly been promising. 8, 9 Only 1 patient in our series (patient 15) had lymph node metastases, in PC and the right pelvic area. Two SNs were found in the lower PC area, one of which was metastatic and predicted correctly the surgical stage of the patient. However, there were no SNs detected in the right pelvic area. In the series by Kleppe et al, 6 also 1 patient had lymph node metastases in SNs and in other regional nodes. She, however, had a final diagnosis of ovarian and synchronous endometrial cancer, and it was not conclusive which cancer the metastases were related to. 6 The number of patients studied is still too small to allow for any conclusions about the reliability of SN concept in ovarian cancer. When adding our results to the study of Kleppe et al, 6 41 ovarian tumor patients have been operated on, 9 lymphadenectomies have been performed, and only 2 patients (5% of all) have had lymph node metastasis. Based on the above figures, to collect data of 20 EOC patients with nodal metastasis, one should include approximately 400 ovarian tumor patients. It is not easy to find suitable patients with suspicious ovarian tumors but no signs of dissemination. Two of our patients (10%) had more advanced disease than was preoperatively assumed. For us, it took several years to gather a series even this large. Obviously only a multicenter study could solve this problem.
We conclude that perioperative 1-spot injection of blue dye and technetium isotope is feasible in detecting SNs in patients with ovarian tumor(s). One to 3 SNs per patient can be found with this method; they are usually ipsilateral, but both bilateral and contralateral SNs are conceivable. Our results confirm that the main lymphatic drainage route from the ovary is to the PA region, the SNs of the left ovary being usually located higher than those of the right ovary. Also, the pelvic SNs related to the left ovary seem to be located higher in the pelvis than those related to the right ovary. The reliability of the SN concept in ovarian cancer and its clinical applications should be evaluated in a larger multicenter study.
